Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gottron's papules-like eruption developing under hydroxyurea therapy.

Gleb Slobodin1, Michael Lurie, Mariana Munichor

  • 1Department of Internal Medicine A, Bnai Zion Medical Center, Haifa, 31048, PO Box 4940, Israel. gslobodin@yahoo.com

Rheumatology International
|April 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CAR-T as a salvage treatment in polyrefractory RA.

Rheumatology (Oxford, England)·2026
Same author

Clinical Images: Bone Buds as Precursors to Ankylosis in Axial Spondyloarthritis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous haematopoietic stem cell transplantation: a case series.

Rheumatology (Oxford, England)·2026
Same author

The Natural History of Deficiency of Adenosine Deaminase 2 Vasculitis in a Large Cohort and Factors Associated With Disease-Related Damage.

The Journal of rheumatology·2026
Same author

Neutrophil-to-lymphocyte ratio as a biomarker for disease onset and mortality risk in SSc: a real-world national cohort study.

Rheumatology (Oxford, England)·2025
Same author

Semaphorin3A Rewires CD4<sup>+</sup> T-Cell Metabolism via AKT/mTORC1 Inhibition in Health and Rheumatoid Arthritis.

International journal of molecular sciences·2025
Same journal

Predominant HLA class I associations with lupus nephritis susceptibility, histology class and reduced renal function in patients with systemic lupus erythematosus: a retrospective case-control study.

Rheumatology international·2026
Same journal

Post-stroke rehabilitation in inflammatory rheumatic diseases: outcome measures, digital tools, and patient education perspectives.

Rheumatology international·2026
Same journal

A diagnostic pitfall in suspected giant cell arteritis: metastatic renal cell carcinoma mimicking the temporal artery halo sign on ultrasound.

Rheumatology international·2026
Same journal

Health education needs of the Brazilian population with rheumatoid arthritis: mixed-methods cross-sectional study.

Rheumatology international·2026
Same journal

Barriers to and facilitators of maintaining physical activity for people with hip and knee osteoarthritis: a mixed-methods systematic review.

Rheumatology international·2026
Same journal

Investigation of factors affecting exercise perception in women with rheumatoid arthritis: a cross-sectional study.

Rheumatology international·2026
See all related articles

Hydroxyurea therapy can cause Gottron

Area of Science:

  • Dermatology
  • Oncology
  • Pharmacology

Background:

  • Dermatomyositis (DM) is an idiopathic inflammatory myopathy.
  • Gottron's papules (GP) are a hallmark cutaneous manifestation of DM.
  • Hydroxyurea is a medication used to treat myeloproliferative neoplasms, including chronic myeloid leukemia.

Observation:

  • A 57-year-old female patient on hydroxyurea for chronic myeloid leukemia developed a GP-like rash.
  • The patient exhibited no other clinical or laboratory findings suggestive of DM.
  • Skin biopsy revealed findings consistent with seborrheic keratosis.

Findings:

  • The patient's eruption mimicked Gottron's papules but was not associated with dermatomyositis.
  • Histopathology confirmed seborrheic keratosis, ruling out DM.

Related Experiment Videos

  • This case highlights hydroxyurea as a potential cause of GP-like skin lesions.

    • Implications:

    • Hydroxyurea-induced skin reactions should be considered in the differential diagnosis of GP-like eruptions.
    • Distinguishing drug-induced lesions from DM is crucial for appropriate patient management.
    • Further research into the dermatologic side effects of hydroxyurea is warranted.